MedTrace Logo

Mobile Chat Messaging for Smoking Relapse Prevention

NCT05370352 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 590

Last updated 2025-11-20

No results posted yet for this study

Summary

Most smokers return to smoking (relapse) after making a quit attempt, but evidence of effective intervention to prevent relapse is scarce. Taking advantage of recent advances in mobile technologies, this study aims to evaluate the effectiveness of a mobile chat messaging-based relapse prevention intervention in promoting successful quitting in people who recently quit smoking (recent abstainers) using a randomised controlled trial design.

Conditions

  • Smoking Cessation

Interventions

BEHAVIORAL

Standard smoking cessation treatment

Standard smoking cessation treatment (behavioural and pharmacotherapy) provided by Tung Wah Group of Hospitals Integrated Centre on Smoking Cessation

BEHAVIORAL

Personalised chat messaging

Personalised chat messaging focusing on smoking relapse prevention for 3 months from randomisation. A trained counsellor will interact with a participant individually and provide relapse prevention advice via WhatsApp. The participant can also access a supportive chatbot in WhatsApp, which will provide on-demand smoking relapse prevention support when the counsellor is not available (e.g., during nighttime).

BEHAVIORAL

SMS text messaging

SMS text messaging on generic information about the harms of smoking and the benefits of quitting for 3 months from randomisation.

Sponsors & Collaborators

  • Health and Medical Research Fund

    collaborator OTHER_GOV

  • Tung Wah Group of Hospitals Integrated Centre on Smoking Cessation

    collaborator UNKNOWN

  • United Christian Nethersole Community Health Service Smoking Cessation Programme

    collaborator UNKNOWN

  • The University of Hong Kong

    lead OTHER

Principal Investigators

  • Tzu Tsun Luk, PhD, RN · The University of Hong Kong

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-03-14
Primary Completion
2025-02-16
Completion
2025-08-10

Countries

  • Hong Kong

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05370352 on ClinicalTrials.gov